Suggestions
Mark Lee
Accelerating Oncology Innovation
Mark Lee is a prominent figure in the medical and healthcare industry, currently serving as the CEO and Co-Founder of N-Power Medicine, Inc., a company he co-founded in May 2021. N-Power Medicine focuses on transforming clinical trials to enhance patient access and accelerate drug development in oncology. Under his leadership, the company has made significant strides, including a recent acquisition of Syapse to expand its capabilities in precision medicine solutions for cancer care.123
Education and Early Career
Mark Lee holds a Bachelor of Science degree in Biological Sciences from Stanford University (1987-1991), followed by a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University (1991-1996). He completed his medical degree (MD) at Stanford University School of Medicine from 1996 to 2000, where he also did his residency in internal medicine and fellowship in medical oncology.23
Professional Experience
Before founding N-Power Medicine, Mark held several key positions:
- SVP and Global Head for Personalized Healthcare, Product Development at Genentech (2017-2021)
- Head of Clinical Development and Medical Affairs at GRAIL, Inc. (2016-2017)
- Part of the Google[x] Life Sciences team (2014-2016)
- Chief Medical Officer at Boreal Genomics (2014)
- Various roles at Genomic Health, including Vice President of Oncology Development (2012-2014) and Associate Medical Director at Genentech (2006) .123
Contributions to Oncology
Mark Lee's work primarily revolves around improving clinical trial accessibility for oncologists and patients. He emphasizes the need for innovative models that allow broader participation in clinical research, aiming to reduce the lengthy timelines traditionally associated with oncology drug development. His vision is to create an integrated approach that combines clinical research with routine patient care, thereby enhancing the overall efficiency of drug development processes.45
In summary, Mark Lee is a seasoned medical oncologist and scientist with extensive experience in both academia and industry, dedicated to advancing cancer treatment through innovative clinical research methodologies.
